Who are clonidine (drug) intravenously's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oxymetazoline-fluticasone propionate, Brimonidine/Timolol mixed combination, dexmedetomidine 1 µg/kg IV, Pregabalin and dexmedetomidine, Catapresan TTS 2, Combigan Ophthalmic Solutiom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clonidine-drug-intravenously.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

clonidine (drug) intravenously — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

clonidine (drug) intravenously (clonidine (drug) intravenously) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Cardiovascular.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

clonidine (drug) intravenously (clonidine (drug) intravenously) — Medical University of Vienna. Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic nervous system activity, lowering blood pressure and heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
clonidine (drug) intravenously TARGET	clonidine (drug) intravenously	Medical University of Vienna	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
dexmedetomidine 1 µg/kg IV	dexmedetomidine 1 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Pregabalin and dexmedetomidine	Pregabalin and dexmedetomidine	Wonkwang University Hospital	marketed	Combination analgesic/sedative (gabapentinoid + alpha-2 agonist)	Alpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine)
Catapresan TTS 2	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Combigan Ophthalmic Solutiom	Combigan Ophthalmic Solutiom	Genovate Biotechnology Co., Ltd.,	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist	Alpha-2 adrenergic receptors and beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). clonidine (drug) intravenously — Competitive Intelligence Brief. https://druglandscape.com/ci/clonidine-drug-intravenously. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab